Antifungal Drugs: The Current Armamentarium and Development of New Agents
The DOI matches its Crossref record; 183 of the 183 references it cites were found in a registry or an index.
Abstract
Invasive fungal infections are becoming an increasingly important cause of human mortality and morbidity, particularly for immunocompromised populations. The fungal pathogens Candida albicans , Cryptococcus neoformans , and Aspergillus fumigatus collectively contribute to over 1 million human deaths annually. Hence, the importance of safe and effective antifungal therapeutics for the practice of modern medicine has never been greater. Given that fungi are eukaryotes like their human host, the number of unique molecular targets that can be exploited for drug development remains limited. Only three classes of molecules are currently approved for the treatment of invasive mycoses. The efficacy of these agents is compromised by host toxicity, fungistatic activity, or the emergence of drug resistance in pathogen populations. Here we describe our current arsenal of antifungals and highlight current strategies that are being employed to improve the therapeutic safety and efficacy of these drugs. We discuss state-of-the-art approaches to discover novel chemical matter with antifungal activity and highlight some of the most promising new targets for antifungal drug development. We feature the benefits of combination therapy as a strategy to expand our current repertoire of antifungals and discuss the antifungal combinations that have shown the greatest potential for clinical development. Despite the paucity of new classes of antifungals that have come to market in recent years, it is clear that by leveraging innovative approaches to drug discovery and cultivating collaborations between academia and industry, there is great potential to bolster the antifungal armamentarium.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tolerance can be affected by several adjuvant drugs 12 , iron levels 26 , and genes involved in vacuolar protein sorting 19 , as well as calcium flux 14,27,28 .”
From Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia (2018) · cites this paper as [12]
In the citing paper
“The current arsenal of antifungal compounds used for the treatment of aspergillosis consists of three classes of antifungal agents, two of them targeting ergosterol, the functional fungal analogue of cholesterol and the major component specific to fungal membranes, and a third class that targets the synthesis of β1,3 glucan, the major component of the fungal cell wall (610–614) (Fig. 20).”
From Aspergillus fumigatus and Aspergillosis in 2019 (2019) · cites this paper as [613]
Citations
Cites
Lead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Functional profiling of the Saccharomyces cerevisiae genome
Giaever, G., Chu, A. M., Ni, L., Connelly, C., Riles, L., Véronneau, S., Dow, S., Lucau-Danila, A., Anderson, K., André, B., et al. (2002) · Nature · doi:10.1038/nature00935 · Cited by 4,316
Hidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284
Functional Characterization of the S. cerevisiae Genome by Gene Deletion and Parallel Analysis
Winzeler, E. A., Shoemaker, D. D., Astromoff, A., Liang, H., Anderson, K., Andre, B., Bangham, R., Benito, R., Boeke, J. D., Bussey, H., et al. (1999) · Science · doi:10.1126/science.285.5429.901 · Cited by 3,953 · cited 1×
“cerevisiae genome are essential for viability (149).”
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Hsp90 as a capacitor for morphological evolution
Rutherford, S. L., & Lindquist, S. (1998) · Nature · doi:10.1038/24550 · Cited by 2,270
Antibacterial drug discovery in the resistance era
Brown, E. D., & Wright, G. D. (2016) · Nature · doi:10.1038/nature17042 · Cited by 2,247
Self-citationThe Genetic Landscape of a Cell
Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E. D., Sevier, C. S., Ding, H., Koh, J. L. Y., Toufighi, K., Mostafavi, S., et al. (2010) · Science · doi:10.1126/science.1180823 · Cited by 2,162 · cited 3×
“Combination therapy also has the potential to unveil myriad additional antifungal targets given that fungal biology is controlled by a highly interconnected and functionally redundant network of biological interactions (147, 148).”
BackgroundGlobal Mapping of the Yeast Genetic Interaction Network
Tong, A. H. Y., Lesage, G., Bader, G. D., Ding, H., Xu, H., Xin, X., Young, J., Berriz, G. F., Brost, R. L., Chang, M., et al. (2004) · Science · doi:10.1126/science.1091317 · Cited by 2,095
Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast
Heitman, J., Movva, N. R., & Hall, M. N. (1991) · Science · doi:10.1126/science.1715094 · Cited by 2,006
TOR, a Central Controller of Cell Growth
Schmelzle, T., & Hall, M. N. (2000) · Cell · doi:10.1016/s0092-8674(00)00117-3 · Cited by 1,924
HSP90 at the hub of protein homeostasis: emerging mechanistic insights
Taipale, M., Jarosz, D. F., & Lindquist, S. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2918 · Cited by 1,818
VÉZINA, C., KUDELSKI, A., & SEHGAL, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,687
Functions of Site-Specific Histone Acetylation and Deacetylation
Shahbazian, M. D., & Grunstein, M. (2007) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.76.052705.162114 · Cited by 1,635
Targeting virulence: a new paradigm for antimicrobial therapy
Clatworthy, A. E., Pierson, E., & Hung, D. T. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.24 · Cited by 1,406
Hsp90 as a capacitor of phenotypic variation
Queitsch, C., Sangster, T. A., & Lindquist, S. (2002) · Nature · doi:10.1038/nature749 · Cited by 1,372
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
Yang, X.-J., & Seto, E. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2346 · Cited by 1,230
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · cited 2×
“Despite their potent activity against Candida and Aspergillus , these compounds are completely ineffective at combating Cryptococcus infections (18).”
BackgroundMulti-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
Structure and mechanism of the Hsp90 molecular chaperone machinery
Pearl, L. H., & Prodromou, C. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142738 · Cited by 1,103
The Chemical Genomic Portrait of Yeast: Uncovering a Phenotype for All Genes
Hillenmeyer, M. E., Fung, E., Wildenhain, J., Pierce, S. E., Hoon, S., Lee, W., Proctor, M., St.Onge, R. P., Tyers, M., Koller, D., et al. (2008) · Science · doi:10.1126/science.1150021 · Cited by 1,003
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844
Zhao, R., Davey, M., Hsu, Y.-C., Kaplanek, P., Tong, A., Parsons, A. B., Krogan, N., Cagney, G., Mai, D., Greenblatt, J., et al. (2005) · Cell · doi:10.1016/j.cell.2004.12.024 · Cited by 819
Amphotericin B formulations: a comparative review of efficacy and toxicity
Hamill, R. J. (2013) · Drugs · doi:10.1007/s40265-013-0069-4 · Cited by 807 · cited 3×
“The large molecular size of the compound results in rapid uptake of the drug by macrophages, which distribute the compound throughout the mononuclear phagocyte system including target organs such as the liver and spleen (19).”
BackgroundInfluentialKidd, S. E., Hagen, F., Tscharke, R. L., Huynh, M., Bartlett, K. H., Fyfe, M., MacDougall, L., Boekhout, T., Kwon-Chung, K. J., & Meyer, W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402981101 · Cited by 756
Multidrug evolutionary strategies to reverse antibiotic resistance
Baym, M., Stone, L. K., & Kishony, R. (2016) · Science · doi:10.1126/science.aad3292 · Cited by 710
Hsp90 Potentiates the Rapid Evolution of New Traits: Drug Resistance in Diverse Fungi
Cowen, L. E., & Lindquist, S. (2005) · Science · doi:10.1126/science.1118370 · Cited by 698 · cited 4×
“Com-promise of Hsp90 function also transforms azoles from fungistatic to fungicidal (82).”
BackgroundInfluentialSelf-citationNoble, S. M., French, S., Kohn, L. A., Chen, V., & Johnson, A. D. (2010) · Nature Genetics · doi:10.1038/ng.605 · Cited by 678
An Antifungal Agent Inhibits an Aminoacyl-tRNA Synthetase by Trapping tRNA in the Editing Site
Rock, F. L., Mao, W., Yaremchuk, A., Tukalo, M., Crépin, T., Zhou, H., Zhang, Y.-K., Hernandez, V., Akama, T., Baker, S. J., et al. (2007) · Science · doi:10.1126/science.1142189 · Cited by 631
Systematic discovery of multicomponent therapeutics
Borisy, A. A., Elliott, P. J., Hurst, N. W., Lee, M. S., Lehár, J., Price, E. R., Serbedzija, G., Zimmermann, G. R., Foley, M. A., Stockwell, B. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1337088100 · Cited by 620 · cited 1×
“cerevisiae have been identified by chemical biology screens (160, 161) and computational methods (162–164).”
BackgroundTargeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614 · cited 1×
“Farnesyltranferase is a ubiquitous eukaryotic enzyme that catalyzes posttranslational lipidation on the C-terminus of more than 120 important signaling proteins in mam-8 malian cells (64).”
BackgroundAntifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches
Roemer, T., & Krysan, D. J. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019703 · Cited by 593
Regulatory circuitry governing fungal development, drug resistance, and disease.
Shapiro, R. S., Robbins, N., & Cowen, L. E. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00045-10 · Cited by 576
Self-citationGenomic profiling of drug sensitivities via induced haploinsufficiency
Giaever, G., Shoemaker, D. D., Jones, T. W., Liang, H., Winzeler, E. A., Astromoff, A., & Davis, R. W. (1999) · Nature Genetics · doi:10.1038/6791 · Cited by 570
Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria
Eastman, R. T., & Fidock, D. A. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2239 · Cited by 568
Combination Antifungal Therapy for Cryptococcal Meningitis
Day, J. N., Chau, T. T. H., Wolbers, M., Mai, P. P., Dung, N. T., Mai, N. H., Phu, N. H., Nghia, H. D., Phong, N. D., Thai, C. Q., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1110404 · Cited by 545
Amphotericin forms an extramembranous and fungicidal sterol sponge
Anderson, T. M., Clay, M. C., Cioffi, A. G., Diaz, K. A., Hisao, G. S., Tuttle, M. D., Nieuwkoop, A. J., Comellas, G., Maryum, N., Wang, S., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1496 · Cited by 528
Calcineurin is required for virulence of Cryptococcus neoformans
Odom, A., Muir, S., Lim, E., Toffaletti, D. L., Perfect, J., & Heitman, J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.10.2576 · Cited by 516
Roemer, T., Jiang, B., Davison, J., Ketela, T., Veillette, K., Breton, A., Tandia, F., Linteau, A., Sillaots, S., Marta, C., et al. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03697.x · Cited by 512
Chemogenomic profiling: Identifying the functional interactions of small molecules in yeast
Giaever, G., Flaherty, P., Kumm, J., Proctor, M., Nislow, C., Jaramillo, D. F., Chu, A. M., Jordan, M. I., Arkin, A. P., & Davis, R. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307490100 · Cited by 504
How to bolster the antifungal pipeline
Denning, D. W., & Bromley, M. J. (2015) · Science · doi:10.1126/science.aaa6097 · Cited by 481
Diverse Cellular Functions of the Hsp90 Molecular Chaperone Uncovered Using Systems Approaches
McClellan, A. J., Xia, Y., Deutschbauer, A. M., Davis, R. W., Gerstein, M., & Frydman, J. (2007) · Cell · doi:10.1016/j.cell.2007.07.036 · Cited by 474
An insight into the antifungal pipeline: selected new molecules and beyond
Ostrosky-Zeichner, L., Casadevall, A., Galgiani, J. N., Odds, F. C., & Rex, J. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3074 · Cited by 432
Cowen, L. E., Singh, S. D., Köhler, J. R., Collins, C., Zaas, A. K., Schell, W. A., Aziz, H., Mylonakis, E., Perfect, J. R., Whitesell, L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813394106 · Cited by 413 · cited 2×
“Furthermore, in murine models of C. albicans disseminated disease, genetic compromise of fungal HSP90 expression reduces virulence (110) and enhances the therapeutic ef fi cacy of fl uconazole and caspofungin (81, 115).”
BackgroundSelf-citationGroll, A. H., Giri, N., Petraitis, V., Petraitiene, R., Candelario, M., Bacher, J. S., Piscitelli, S. C., & Walsh, T. J. (2000) · The Journal of Infectious Diseases · doi:10.1086/315643 · Cited by 373
Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin
Singh, S. D., Robbins, N., Zaas, A. K., Schell, W. A., Perfect, J. R., & Cowen, L. E. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000532 · Cited by 362 · cited 4×
“Biochemical analysis con fi rmed that Hsp90 stabilizes the catalytic subunit of calcineurin and the terminal MAP kinase of the Pkc1 cell wall integrity pathway, Mkc1 (81, 105).”
BackgroundInfluentialSelf-citationHsp90 and Environmental Stress Transform the Adaptive Value of Natural Genetic Variation
Jarosz, D. F., & Lindquist, S. (2010) · Science · doi:10.1126/science.1195487 · Cited by 346 · cited 1×
“As a consequence of its role in stabilizing key signal transducers, Hsp90 modulates the relationship between genotype and phenotype by acting as both a capacitor and a potentiator for the storage and release of genetic variation (95 – 97).”
BackgroundCalcineurin is essential for survival during membrane stress in Candida albicans
Cruz, M. C., Goldstein, A. L., Blankenship, J. R., Del Poeta, M., Davis, D., Cardenas, M. E., Perfect, J. R., McCusker, J. H., & Heitman, J. (2002) · The EMBO Journal · doi:10.1093/emboj/21.4.546 · Cited by 342
Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent
Miceli, M. H., & Kauffman, C. A. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ571 · Cited by 338
Byrnes, E. J., Li, W., Lewit, Y., Ma, H., Voelz, K., Ren, P., Carter, D. A., Chaturvedi, V., Bildfell, R. J., May, R. C., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000850 · Cited by 330 · cited 2×
“walls are composed of (1,3)-β-D-glucans covalently linked to (1,6)-β-D-glucans as well as”
BackgroundLaFayette, S. L., Collins, C., Zaas, A. K., Schell, W. A., Betancourt-Quiroz, M., Gunatilaka, A. A. L., Perfect, J. R., & Cowen, L. E. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001069 · Cited by 329 · cited 5×
“In a series of clinical isolates recovered over time from an HIV-infected patient treated with fl uconazole, the basal fl uconazole resistance phenotypes of isolates recovered early during treatment were dependent on Hsp90, calcineurin, and Pkc1 function (82, 105).”
BackgroundInfluentialSelf-citationDiscovery of Novel Antifungal (1,3)-β- d -Glucan Synthase Inhibitors
Onishi, J., Meinz, M., Thompson, J., Curotto, J., Dreikorn, S., Rosenbach, M., Douglas, C., Abruzzo, G., Flattery, A., Kong, L., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.2.368-377.2000 · Cited by 326
A neglected epidemic: Fungal infections in HIV/AIDS
Armstrong-James, D., Meintjes, G., & Brown, G. D. (2014) · Trends in Microbiology · doi:10.1016/j.tim.2014.01.001 · Cited by 325
Fitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B
Vincent, B. M., Lancaster, A. K., Scherz-Shouval, R., Whitesell, L., & Lindquist, S. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001692 · Cited by 322 · cited 1×
“Given that polyfunctional lipids such as ergosterol serve as central molecular nodes in cellular physiology and function, resistance to the polyenes is strongly evaded and comes at a significant fitness cost to the fungus (11).”
BackgroundHarnessing calcineurin as a novel anti-infective agent against invasive fungal infections.
Steinbach, W. J., Reedy, J. L., Cramer, R. A., Perfect, J. R., & Heitman, J. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1680 · Cited by 313
Hsp90 Orchestrates Temperature-Dependent Candida albicans Morphogenesis via Ras1-PKA Signaling
Shapiro, R. S., Uppuluri, P., Zaas, A. K., Collins, C., Senn, H., Perfect, J. R., Heitman, J., & Cowen, L. E. (2009) · Current Biology · doi:10.1016/j.cub.2009.03.017 · Cited by 311
Self-citationThe evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype.
Cowen, L. E. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1835 · Cited by 311
Self-citationHsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms
Robbins, N., Uppuluri, P., Nett, J., Rajendran, R., Ramage, G., Lopez-Ribot, J. L., Andes, D., & Cowen, L. E. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002257 · Cited by 291
Self-citationOnyewu, C., Blankenship, J. R., Del Poeta, M., & Heitman, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.956-964.2003 · Cited by 282
Chemical combination effects predict connectivity in biological systems
Lehár, J., Zimmermann, G. R., Krueger, A. S., Molnar, R. A., Ledell, J. T., Heilbut, A. M., Short, G. F., Giusti, L. C., Nolan, G. P., Magid, O. A., et al. (2007) · Molecular Systems Biology · doi:10.1038/msb4100116 · Cited by 275
Daptomycin: mechanisms of action and resistance, and biosynthetic engineering
Baltz, R. H. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.02.031 · Cited by 267
Mapping the Cellular Response to Small Molecules Using Chemogenomic Fitness Signatures
Spear, E. D., & Kaiser, C. A. (2013) · DSpace@MIT (Massachusetts Institute of Technology) · Cited by 266
Mapping the Cellular Response to Small Molecules Using Chemogenomic Fitness Signatures
Lee, A. Y., St.Onge, R. P., Proctor, M. J., Wallace, I. M., Nile, A. H., Spagnuolo, P. A., Jitkova, Y., Gronda, M., Wu, Y., Kim, M. K., et al. (2014) · Science · doi:10.1126/science.1250217 · Cited by 259
Genome-Wide Fitness Test and Mechanism-of-Action Studies of Inhibitory Compounds in Candida albicans
Xu, D., Jiang, B., Ketela, T., Lemieux, S., Veillette, K., Martel, N., Davison, J., Sillaots, S., Trosok, S., Bachewich, C., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030092 · Cited by 254
Zhang, L., Yan, K., Zhang, Y., Huang, R., Bian, J., Zheng, C., Sun, H., Chen, Z., Sun, N., An, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609370104 · Cited by 248
Global analysis of fungal morphology exposes mechanisms of host cell escape
O’Meara, T. R., Veri, A. O., Ketela, T., Jiang, B., Roemer, T., & Cowen, L. E. (2015) · Nature Communications · doi:10.1038/ncomms7741 · Cited by 243 · cited 1×
“It is becoming abundantly clear that gene essentiality and chemicalgenetic responses diverge rapidly over evolutionary time (175, 176), underscoring the importance of performing”
BackgroundSelf-citationGlucosylceramide synthase is an essential regulator of pathogenicity of Cryptococcus neoformans
Rittershaus, P. C. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27890 · Cited by 239
Synergistic Effect of Calcineurin Inhibitors and Fluconazole against Candida albicans Biofilms
Uppuluri, P., Nett, J., Heitman, J., & Andes, D. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01397-07 · Cited by 228
Cell growth control: little eukaryotes make big contributions
De Virgilio, C., & Loewith, R. (2006) · Oncogene · doi:10.1038/sj.onc.1209884 · Cited by 218
Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata
Singh-Babak, S. D., Babak, T., Diezmann, S., Hill, J. A., Xie, J. L., Chen, Y.-L., Poutanen, S. M., Rennie, R. P., Heitman, J., & Cowen, L. E. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002718 · Cited by 205
Self-citationZhai, B., Wu, C., Wang, L., Sachs, M. S., & Lin, X. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00212-12 · Cited by 205 · cited 1×
“Other notable examples include potentiation of azole activity by pharmacological inhibition of ADPribosylation factors (154), protein kinase C (105), and protein translation (155).”
BackgroundThe Ras/cAMP/PKA signaling pathway and virulence in Candida albicans
Hogan, D. A., & Sundstrom, P. (2009) · Future Microbiology · doi:10.2217/fmb.09.106 · Cited by 186
Cross‐species discovery of syncretic drug combinations that potentiate the antifungal fluconazole
Spitzer, M., Griffiths, E., Blakely, K. M., Wildenhain, J., Ejim, L., Rossi, L., De Pascale, G., Curak, J., Brown, E., Tyers, M., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.31 · Cited by 183
Self-citationTherapeutic potential of antifungal plant and insect defensins
Thevissen, K., Kristensen, H.-H., Thomma, B. P. H. J., Cammue, B. P. A., & François, I. E. J. A. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.07.016 · Cited by 179
Targeting virulence: A new paradigm for antifungals
Gauwerky, K., Borelli, C., & Korting, H. C. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.11.013 · Cited by 174
New and emerging treatments for fungal infections
Pasqualotto, A. C., & Denning, D. W. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm428 · Cited by 173 · cited 1×
“The prodrug, termed BAL-8557, becomes cleaved in a reaction catalyzed by plasma esterases in mammalian cells ( 30).”
BackgroundManaging drug resistance in cancer: lessons from HIV therapy
Bock, C., & Lengauer, T. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3297 · Cited by 170
Cruz, M. C., Cavallo, L. M., Görlach, J. M., Cox, G., Perfect, J. R., Cardenas, M. E., & Heitman, J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.6.4101 · Cited by 169
Lee, S. C., Li, A., Calo, S., & Heitman, J. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003625 · Cited by 169
He, B., Chen, P., Chen, S. Y., Vancura, K. L., Michaelis, S., & Powers, S. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.24.11373 · Cited by 168
Genome-Wide Requirements for Resistance to Functionally Distinct DNA-Damaging Agents
Lee, W., St.Onge, R. P., Proctor, M., Flaherty, P., Jordan, M. I., Arkin, A. P., Davis, R. W., Nislow, C., & Giaever, G. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0010024 · Cited by 164
John, A. R. O., Poeta, M. D., Perfect, J. R., & Heitman, J. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.1.156 · Cited by 161
Systems-level antimicrobial drug and drug synergy discovery
Roemer, T., & Boone, C. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1205 · Cited by 159
Cruz, M. C., Goldstein, A. L., Blankenship, J., Del Poeta, M., Perfect, J. R., McCusker, J. H., Bennani, Y. L., Cardenas, M. E., & Heitman, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.11.3162-3170.2001 · Cited by 159
Genetic Architecture of Hsp90-Dependent Drug Resistance
Cowen, L. E., Carpenter, A. E., Matangkasombut, O., Fink, G. R., & Lindquist, S. (2006) · Eukaryotic Cell · doi:10.1128/ec.00274-06 · Cited by 159 · cited 2×
“Pharmacological inhibition of calcineurin in C. neo-formans abrogates growth at 37°C (78), potentiates the activity of both azoles and echinocandins in C. albicans (79 – 83), and renders the fungistatic azoles fungicidal against multiple Candida species (84).”
BackgroundSelf-citationLoyse, A., Dromer, F., Day, J., Lortholary, O., & Harrison, T. S. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt221 · Cited by 158
Modulation of histone H3 lysine 56 acetylation as an antifungal therapeutic strategy
Wurtele, H., Tsao, S., Lépine, G., Mullick, A., Tremblay, J., Drogaris, P., Lee, E.-H., Thibault, P., Verreault, A., & Raymond, M. (2010) · Nature Medicine · doi:10.1038/nm.2175 · Cited by 157
Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis
Santangelo, R., Paderu, P., Delmas, G., Chen, Z.-W., Mannino, R., Zarif, L., & Perlin, D. S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2356-2360.2000 · Cited by 150 · cited 2×
“A cochle-ate formulation of amphotericin B displayed ef fi cacy in experimental models of candidiasis and aspergillosis (24 – 26).”
BackgroundHata, K., Horii, T., Miyazaki, M., Watanabe, N.-A., Okubo, M., Sonoda, J., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00366-11 · Cited by 149 · cited 1×
“chemical-based optimization led to development of the pyridine-2-amine-based molecule E1210, a compound with potent antifungal activity against numerous pathogenic fungi (61).”
BackgroundDark chemical matter as a promising starting point for drug lead discovery
Wassermann, A. M., Lounkine, E., Hoepfner, D., Goff, G. L., King, F. J., Studer, C., Peltier, J. M., Grippo, M. L., Prindle, V. C., Tao, J., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1936 · Cited by 148
Confronting the challenges of natural product-based antifungal discovery
Roemer, T., Xu, D., Singh, S. B., Parish, C. A., Harris, G., Wang, H., Davies, J. E., & Bills, G. F. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.01.009 · Cited by 147
Smith, W. L., & Edlind, T. D. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3532-3539.2002 · Cited by 147
Inhibiting fungal multidrug resistance by disrupting an activator–Mediator interaction
Nishikawa, J. L., Boeszoermenyi, A., Vale-Silva, L. A., Torelli, R., Posteraro, B., Sohn, Y.-J., Ji, F., Gelev, V., Sanglard, D., Sanguinetti, M., et al. (2016) · Nature · doi:10.1038/nature16963 · Cited by 146 · cited 3×
“metazoan and mammalian models of infection (159).”
BackgroundInfluentialIdentification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids
Mor, V., Rella, A., Farnoud, A. M., Singh, A., Munshi, M., Bryan, A., Naseem, S., Konopka, J. B., Ojima, I., Bullesbach, E., et al. (2015) · mBio · doi:10.1128/mbio.00647-15 · Cited by 144
In Vitro Interactions between Antifungals and Immunosuppressants against Aspergillus fumigatus
Steinbach, W. J., Schell, W. A., Blankenship, J. R., Onyewu, C., Heitman, J., & Perfect, J. R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1664-1669.2004 · Cited by 143
Pfaller, M. A., Messer, S. A., Georgopapadakou, N., Martell, L. A., Besterman, J. M., & Diekema, D. J. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.00618-09 · Cited by 143
Good fungi gone bad: The corruption of calcineurin
Fox, D. S., & Heitman, J. (2002) · BioEssays · doi:10.1002/bies.10157 · Cited by 137 · cited 2×
“In pathogenic fungi, calcineurin regulates myriad physiological processes including cell cycle progression, cation homeostasis, morphogenesis, virulence, and antifungal drug responses (76, 77).”
BackgroundHeat Shock Protein 90 Is Required for Conidiation and Cell Wall Integrity in Aspergillus fumigatus
Lamoth, F., Juvvadi, P. R., Fortwendel, J. R., & Steinbach, W. J. (2012) · Eukaryotic Cell · doi:10.1128/ec.00032-12 · Cited by 136
Tsukahara, K., Hata, K., Nakamoto, K., Sagane, K., Watanabe, N., Kuromitsu, J., Kai, J., Tsuchiya, M., Ohba, F., Jigami, Y., et al. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03481.x · Cited by 135
Bugs, drugs and chemical genomics
Roemer, T., DAVIES, J. E., Giaever, G. N., & Nislow, C. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.744 · Cited by 134
Wright, G. D. (2015) · ACS Infectious Diseases · doi:10.1021/id500052s · Cited by 133
Self-citationHistone acetyltransferase Rtt109 is required for Candida albicans pathogenesis
Lopes da Rosa, J., Boyartchuk, V. L., Zhu, L. J., & Kaufman, P. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912427107 · Cited by 132
Wiederhold, N. P., Kontoyiannis, D. P., Prince, R. A., & Lewis, R. E. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.12.5146-5148.2005 · Cited by 131
Pouliot, M., & Jeanmart, S. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00361 · Cited by 126
Lysine Deacetylases Hda1 and Rpd3 Regulate Hsp90 Function thereby Governing Fungal Drug Resistance
Robbins, N., Leach, M. D., & Cowen, L. E. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.08.035 · Cited by 126
Self-citationAntifungal Activity of Amphotericin B Cochleates against Candida albicans Infection in a Mouse Model
Zarif, L., Graybill, J. R., Perlin, D., Najvar, L., Bocanegra, R., & Mannino, R. J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1463-1469.2000 · Cited by 122
Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning
Wildenhain, J., Spitzer, M., Dolma, S., Jarvik, N., White, R., Roy, M., Griffiths, E., Bellows, D. S., Wright, G. D., & Tyers, M. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.003 · Cited by 121
Self-citationSeiradake, E., Mao, W., Hernandez, V. S., Baker, S. J., Plattner, J. J., Alley, M. R. K., & Cusack, S. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.04.073 · Cited by 118
Wilcock, B. C., Endo, M. M., Uno, B. E., & Burke, M. D. (2013) · Journal of the American Chemical Society · doi:10.1021/ja403255s · Cited by 117
Kontoyiannis, D. P., Lewis, R. E., Osherov, N., Albert, N. D., & May, G. S. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg090 · Cited by 116
Cornely, O. A., Böhme, A., Schmitt‐Hoffmann, A. H., & Ullmann, A. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04569-14 · Cited by 115
McLellan, C. A., Whitesell, L., King, O. D., Lancaster, A. K., Mazitschek, R., & Lindquist, S. (2012) · ACS Chemical Biology · doi:10.1021/cb300235m · Cited by 115
Biosynthesis of Glycosylphosphatidylinositols in Mammals and Unicellular Microbes
Tiede, A., Bastisch, I., Schubert, J. E. A., Orlean, P., & Schmidt, R. E. (1999) · Biological Chemistry · doi:10.1515/bc.1999.066 · Cited by 113
Diezmann, S., Michaut, M., Shapiro, R. S., Bader, G. D., & Cowen, L. E. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002562 · Cited by 112 · cited 1×
“cellular responses to azoles and echinocandins (109), suggesting that Hsp90 may have pleiotropic effects on circuitry governing drug resistance.”
BackgroundSelf-citationEfficacy of Orally Delivered Cochleates Containing Amphotericin B in a Murine Model of Aspergillosis
Delmas, G., Park, S., Chen, Z. W., Tan, F., Kashiwazaki, R., Zarif, L., & Perlin, D. S. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2704-2707.2002 · Cited by 110
Lugardon, K., Chasserot‐Golaz, S., Kieffer, A., Maget‐Dana, R., Nullans, G., Kieffer, B., Aunis, D., & Metz‐Boutigue, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104670200 · Cited by 106
Nontoxic antimicrobials that evade drug resistance
Davis, S. A., Vincent, B., Endo, M. M., Whitesell, L. J., Marchillo, K., Andes, D. R., Lindquist, S. L., & Burke, M. D. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1821 · Cited by 105
The fungal Achilles’ heel: targeting Hsp90 to cripple fungal pathogens
Cowen, L. E. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.03.005 · Cited by 104
Self-citationButts, A., Koselny, K., Chabrier-Roselló, Y., Semighini, C. P., Brown, J. C. S., Wang, X., Annadurai, S., DiDone, L., Tabroff, J., Childers, W. E., et al. (2014) · mBio · doi:10.1128/mbio.00765-13 · Cited by 102
Pfaller, M. A., Messer, S. A., Motyl, M. R., Jones, R. N., & Castanheira, M. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks466 · Cited by 100
Pfaller, M. A., Messer, S. A., Motyl, M. R., Jones, R. N., & Castanheira, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01588-12 · Cited by 98
Lee, S. C., Li, A., Calo, S., Inoue, M., Tonthat, N. K., Bain, J. M., Louw, J., Shinohara, M. L., Erwig, L. P., Schumacher, M. A., et al. (2015) · Molecular Microbiology · doi:10.1111/mmi.13071 · Cited by 95
Li, H., Zhou, H., Luo, Y., Ouyang, H., Hu, H., & Jin, C. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.05709.x · Cited by 95
Butts, A., DiDone, L., Koselny, K., Baxter, B. K., Chabrier-Rosello, Y., Wellington, M., & Krysan, D. J. (2013) · Eukaryotic Cell · doi:10.1128/ec.00314-12 · Cited by 95 · cited 1×
“neoformans (156) and potentiate the activity of azoles, polyenes, and echinocandins in diverse fungal species (157).”
BackgroundRomano, J., Nimrod, G., Ben‐Tal, N., Shadkchan, Y., Baruch, K., Sharon, H., & Osherov, N. (2006) · Microbiology · doi:10.1099/mic.0.28936-0 · Cited by 93
Lamoth, F., Juvvadi, P. R., Gehrke, C., & Steinbach, W. J. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01857-12 · Cited by 88 · cited 1×
“Calcineurin inhibitors also show potent activity against azole-and echinocandin-resistant strains of A. fumigatus (88).”
BackgroundSellam, A., Askew, C., Epp, E., Lavoie, H., Whiteway, M., & Nantel, A. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-11-1093 · Cited by 87
The Hsp90 Co-Chaperone Sgt1 Governs Candida albicans Morphogenesis and Drug Resistance
Shapiro, R. S., Zaas, A. K., Betancourt-Quiroz, M., Perfect, J. R., & Cowen, L. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044734 · Cited by 86 · cited 1×
“Genetic or pharmacological inhibition of Hsp90 function induces filamentation by relieving its repression on Ras1-protein kinase A signaling (110, 111).”
BackgroundSelf-citationJiang, B., Xu, D., Allocco, J., Parish, C. A., Davison, J., Veillette, K., Sillaots, S., Hu, W., Rodriguez-Suarez, R. J., Trosok, S., et al. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.02.016 · Cited by 85
Chemogenomic profiling predicts antifungal synergies
Jansen, G., Lee, A. Y., Epp, E., Fredette, A., Surprenant, J., Harcus, D., Scott, M. S., Tan, E., Nishimura, T., Whiteway, M. S., et al. (2009) · Molecular Systems Biology · doi:10.1038/msb.2009.95 · Cited by 84
Stress Signaling Pathways for the Pathogenicity of Cryptococcus
Bahn, Y.-S., & Jung, K.-W. (2013) · Eukaryotic Cell · doi:10.1128/ec.00218-13 · Cited by 84
Unraveling the Biology of a Fungal Meningitis Pathogen Using Chemical Genetics
Brown, J. C. S., Nelson, J., VanderSluis, B., Deshpande, R., Butts, A., Kagan, S., Polacheck, I., Krysan, D. J., Myers, C. L., & Madhani, H. D. (2014) · Cell · doi:10.1016/j.cell.2014.10.044 · Cited by 84 · cited 1×
“It is becoming abundantly clear that gene essentiality and chemicalgenetic responses diverge rapidly over evolutionary time (175, 176), underscoring the importance of performing”
Richard, M. L., Ibata‐Ombetta, S., Dromer, F., Bordon, F., Jouault, T., & Gaillardin, C. M. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02926.x · Cited by 83
Rodrigues, M. L., Li, S., Barreto‐Bergter, E., Nimrichter, L., Farias, S. E., Rodrigues, E. G., Travassos, L. R., & Nosanchuk, J. D. (2007) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00202-07 · Cited by 83
A Functional Variomics Tool for Discovering Drug-Resistance Genes and Drug Targets
Huang, Z., Chen, K., Zhang, J., Li, Y., Wang, H., Cui, D., Tang, J., Liu, Y., Shi, X., Li, W., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.01.019 · Cited by 81
Heat shock protein 90 (Hsp90): A novel antifungal target against Aspergillus fumigatus
Lamoth, F., Juvvadi, P. R., & Steinbach, W. J. (2014) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2014.947239 · Cited by 81
Shapiro, R. S., Sellam, A., Tebbji, F., Whiteway, M., Nantel, A., & Cowen, L. E. (2012) · Current Biology · doi:10.1016/j.cub.2012.01.062 · Cited by 81
Self-citationFitness Trade-Offs Associated with the Evolution of Resistance to Antifungal Drug Combinations
Hill, J. A., O’Meara, T. R., & Cowen, L. E. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.009 · Cited by 80 · cited 1×
“ing with upregulation of multidrug transporters (82, 105, 106).”
BackgroundSelf-citationRobbins, N., Spitzer, M., Yu, T., Cerone, R. P., Averette, A. K., Bahn, Y.-S., Heitman, J., Sheppard, D. C., Tyers, M., & Wright, G. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.018 · Cited by 78
Self-citationJames, K. D., Laudeman, C. P., Malkar, N. B., Krishnan, R., & Polowy, K. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01541-16 · Cited by 77
Disruption of Sphingolipid Biosynthesis Blocks Phagocytosis of Candida albicans
Tafesse, F., Rashidfarrokhi, A., Schmidt, F. I., Freinkman, E., Dougan, S. K., Dougan, M. L., Esteban, A., Maruyama, T., Strijbis, K., & Ploegh, H. L. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005188 · Cited by 75
Using Combination Therapy to Thwart Drug Resistance
Hill, J. A., & Cowen, L. E. (2015) · Future Microbiology · doi:10.2217/fmb.15.68 · Cited by 75
Self-citationLamoth, F., Juvvadi, P. R., Soderblom, E. J., Moseley, M. A., Asfaw, Y. G., & Steinbach, W. J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02286-13 · Cited by 74
Lo, Y.-C., Senese, S., Li, C.-M., Hu, Q., Huang, Y., Damoiseaux, R., & Torres, J. Z. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004153 · Cited by 72
Panepinto, J. C., Oliver, B. G., Fortwendel, J. R., Smith, D. L. H., Askew, D. S., & Rhodes, J. C. (2003) · Infection and Immunity · doi:10.1128/iai.71.5.2819-2826.2003 · Cited by 72 · cited 1×
“fumigatus, which is important for fungal pathogenesis and vegetative growth in vitro and for virulence in an in vivo model of infection (75).”
BackgroundFortwendel, J. R., Juvvadi, P. R., Rogg, L. E., Asfaw, Y. G., Burns, K. A., Randell, S. H., & Steinbach, W. J. (2012) · Eukaryotic Cell · doi:10.1128/ec.00091-12 · Cited by 71
Timmers, G. J., Zweegman, S., Simoons‐Smit, A. M., Loenen, A. C. V., Touw, D. J., & Huijgens, P. C. (2000) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1702243 · Cited by 70
Paquet, V., & Carreira, E. M. (2006) · Organic Letters · doi:10.1021/ol060353o · Cited by 68
Pfaller, M. A., Rhomberg, P. R., Messer, S. A., & Castanheira, M. (2015) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.11.008 · Cited by 67 · cited 7×
“Deletion of both HDA1 and RPD3 does not increase global Hsp90 acetylation levels, suggesting that additional KDACs orchestrate Hsp90 deacetylation.”
BackgroundInfluentialSenn, H., Shapiro, R. S., & Cowen, L. E. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-08-0729 · Cited by 67
Self-citationSimitsopoulou, M., Roilides, E., Dotis, J., Dalakiouridou, M., Dudkova, F., Andreadou, E., & Walsh, T. J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1397-1403.2005 · Cited by 66
Organization of antibiotic amphotericin B in model lipid membranes. A mini review.
Gruszecki, W. I., Gagoś, M., Hereć, M., & Kernen, P. (2003) · PubMed · Cited by 64
Hast, M. A., Nichols, C. B., Armstrong, S. M., Kelly, S. M., Hellinga, H. W., Alspaugh, J. A., & Beese, L. S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.250506 · Cited by 63
Cordeiro, R. D. A., Evangelista, A. J. D. J., Serpa, R., Marques, F. J. D. F., Melo, C. V. S. D., Oliveira, J. S. D., Franco, J. D. S., Alencar, L. P. D., Bandeira, T. D. J. P. G., Brilhante, R. S. N., et al. (2016) · Microbiology · doi:10.1099/mic.0.000222 · Cited by 63
Lamoth, F., Juvvadi, P. R., Gehrke, C., Asfaw, Y. G., & Steinbach, W. J. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit530 · Cited by 62 · cited 1×
“fumigatus Hsp90 abrogates virulence in a murine model of invasive aspergillosis (104).”
BackgroundVerwer, P. E. B., VanDuijn, M. M., Tavakol, M., Bakker‐Woudenberg, I. A. J. M., & van de Sande, W. W. J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05323-11 · Cited by 62
Epp, E., Vanier, G., Harcus, D., Lee, A. Y., Jansen, G., Hallett, M., Sheppard, D. C., Thomas, D. Y., Munro, C. A., Mullick, A., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000753 · Cited by 61
Advancing the development of tuberculosis therapy
Zumla, A. I., Hafner, R., Lienhardt, C., Höelscher, M., & Nunn, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3694 · Cited by 58
Vallim, M. A., Fernandes, L., & Alspaugh, J. A. (2004) · Microbiology · doi:10.1099/mic.0.27030-0 · Cited by 55
Shapiro, R. S., & Cowen, L. E. (2010) · Virulence · doi:10.4161/viru.1.1.10320 · Cited by 55
Self-citationSafety and Efficacy of Amphotericin B Colloidal Dispersion
Herbrecht, R., Letscher, V., Andres, E., & Cavalier, A. (1999) · Chemotherapy · doi:10.1159/000048472 · Cited by 51
Progress and prospects for targeting Hsp90 to treat fungal infections
Veri, A. O., & Cowen, L. E. (2014) · Parasitology · doi:10.1017/s0031182013002072 · Cited by 49
Self-citationWONG, G. K., GRIFFITH, S., Kojima, I., & Demain, A. L. (1998) · The Journal of Antibiotics · doi:10.7164/antibiotics.51.487 · Cited by 45
Sandovsky‐Losica, H., Shwartzman, R., Lahat, Y., & Segal, E. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn216 · Cited by 42
Warn, P. A., Sharp, J., Morrissey, G., & Denning, D. W. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.09.029 · Cited by 41
Metabolic control of antifungal drug resistance
Robbins, N., Collins, C., Morhayim, J., & Cowen, L. E. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.07.004 · Cited by 40 · cited 1×
“(133, 134) and abrogates erg3mediated azole resistance (135).”
BackgroundSelf-citationXu, D., Ondeyka, J. G., Harris, G. H., Zink, D. L., Kahn, J. N., Wang, H., Bills, G. F., Platas, G., Wang, W., Szewczak, A. A., et al. (2011) · Journal of Natural Products · doi:10.1021/np2001573 · Cited by 40
Yan, J., Du, T., Zhao, W., Hartmann, T., Lu, H., Lü, Y., Ouyang, H., Jiang, X., Sun, L., & Jin, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059013 · Cited by 39
RAM2: an essential gene in the prenylation pathway of Candida albicans
Song, J. L. (2003) · Microbiology · doi:10.1099/mic.0.25887-0 · Cited by 38
Warn, P. A., Sharp, J., Morrissey, G., & Denning, D. W. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki268 · Cited by 35
Shen, H., Chen, S. M., Liu, W., Zhu, F., He, L. J., Zhang, J. D., Zhang, S. Q., Yan, L., Xu, Z. Q., Xu, G. T., et al. (2015) · Infection and Immunity · doi:10.1128/iai.00097-15 · Cited by 30
Rhome, R. M., Singh, A., Kechichian, T. B., Drago, M., Morace, G., Luberto, C., & Poeta, M. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015572 · Cited by 29
McGeady, P., Logan, D. A., & Wansley, D. L. (2002) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2002.tb11283.x · Cited by 26
Mabanglo, M. F., Hast, M. A., Lubock, N. B., Hellinga, H. W., & Beese, L. S. (2013) · Protein Science · doi:10.1002/pro.2411 · Cited by 24
New targets in the search for preventive and therapeutic agents for botulism
Anniballi, F., Lonati, D., Fiore, A., Auricchio, B., Medici, D. D., & Locatelli, C. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.945917 · Cited by 23
Isavuconazole: a role for the newest broad-spectrum triazole
Slavin, M. A., & Thursky, K. (2015) · The Lancet · doi:10.1016/s0140-6736(15)01218-0 · Cited by 22
Organization of antibiotic amphotericin B in model lipid membranes
Gruszecki, W. I., Gagoś, M., Hereć, M., & Kernen, P. (2002) · Cellular & Molecular Biology Letters · Cited by 18
Pries, V., Cotesta, S., Riedl, R., Aust, T., Schuierer, S., Tao, J., Filipuzzi, I., & Hoepfner, D. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115610488 · Cited by 17
Qiao, J., Gao, P., Jiang, X., & Fang, H. (2013) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-12-37 · Cited by 13
Vaccine strategies for infectious diseases
Clerici, M., Piconi, S., & Trabattoni, D. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.2.95 · Cited by 7
Research works printed but not linked: 1
- CDC. 2013. Antibiotic Resistance Threats in the United States 2013 . CDC Atlanta GA. [PubMed]
Cited by
Aspergillus fumigatus and Aspergillosis in 2019
Latgé, J.-P., & Chamilos, G. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00140-18 · Cited by 1,400
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Self-citationThreats Posed by the Fungal Kingdom to Humans, Wildlife, and Agriculture
Fisher, M. C., Gurr, S. J., Cuomo, C. A., Blehert, D. S., Jin, H., Stukenbrock, E. H., Stajich, J. E., Kahmann, R., Boone, C., Denning, D. W., et al. (2020) · mBio · doi:10.1128/mbio.00449-20 · Cited by 536
Self-citationMolecular Evolution of Antifungal Drug Resistance
Robbins, N., Caplan, T., & Cowen, L. E. (2017) · Annual Review of Microbiology · doi:10.1146/annurev-micro-030117-020345 · Cited by 441
Self-citationCyclic peptide drugs approved in the last two decades (2001–2021)
Zhang, H., & Chen, S. (2022) · RSC Chemical Biology · doi:10.1039/d1cb00154j · Cited by 319
Metadata
- Authors
- Robbins, N., Wright, G. D., & Cowen, L. E.
- Affiliations
- Michael G. DeGroote Institute for Infectious Disease Research (CA)
- University of Toronto (CA)
- Venue
- Microbiology Spectrum
- Publisher
- American Society for Microbiology
- Published
- 2016-10-14
- Volume
- 4
- Issue
- 5
- ISSN
- 2165-0497 (ISSN-L)
- OpenAlex
- W2532305189
- Cited by
- 271
- References
- 182
- Citations by year
- 2026: 24 · 2025: 46 · 2024: 46 · 2023: 45 · 2022: 22 · 2021: 29 · 2020: 27 · 2019: 17 · 2018: 10 · 2017: 5
- FWCI
- 9.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Microbiology Spectrum (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- antifungal agents, invasive fungal infections, antifungal resistance, Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus, antifungal drug development, antifungal drug targets, combination antifungal therapy, drug toxicity, immunocompromised patients, novel antifungal agents
- MeSH terms
- Animals, Antifungal Agents, Fungi, Humans, Mycoses
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.